P3 Health Partners Inc. Class A (PIII)

P3 Health Partners announced its second-quarter 2025 results, reporting a 6% decrease in total revenue and outlined a $120 million to $170 million EBITDA improvement opportunity for 2026. The company announced its third-quarter 2025 results, reporting a 5% decrease in total revenue and an adjusted EBITDA loss of $45.9 million, and raised its FY25 revenue view. Lake Street Capital Markets maintained a "Buy" recommendation but lowered its price target, which was further decreased on December 6, 2025. P3 Health Partners faced a Nasdaq compliance challenge. The company expanded its footprint through a joint venture with Commonwealth Primary Care ACO. PIII stock has experienced significant volatility, decreasing by 38.4% since January 1, 2026, and delivering an -81.00% change over the past year.

P3 Health Partners primarily focuses on managing care for Medicare Advantage members, and the demand for its services is inherently linked to Medicare Advantage enrollment patterns. Enrollment periods and reporting cycles for Medicare Advantage plans could introduce some indirect seasonality in the company's operations and financial reporting. The pace of increase in Medicare Advantage enrollment slowed in 2025.

P3 Health Partners, Inc. is a patient-centered and physician-led population health management company that provides professional support services to doctors and clinicians. Its core offerings include a capital-efficient care model, data and technology solutions, physician leadership, and community outreach tools. P3 Health Partners also focuses on quality measurement and reporting, risk adjustment coding and audit services, and population health analytics. The company operates clinics and wellness centers in the United States.

P3 Health Partners, Inc. provides care services across the United States, managing care for Medicare Advantage patients through a network of primary care clinics and over 3,100 affiliated primary care providers across Arizona, California, Nevada, and Oregon. The company's headquarters are located in Henderson, Nevada. P3 Health Partners-Florida, a separate entity, is headquartered in St. Petersburg, FL, and was acquired by Florida Elite Management in November 2024.

P3 Health Partners has a "Hold" consensus rating from analysts, with an average rating score of 2.00. MarketBeat indicates that P3 Health Partners scored higher than 73% of companies evaluated and ranked 231st out of 872 stocks in the medical sector. However, the company has underperformed both the US Healthcare industry and the broader US Market over the past year. A notable event that could impact its reputation is the Nasdaq compliance challenge reported on November 28, 2025.

P3 Health Partners, Inc. has a mixed ownership structure. Major institutional owners include Alyeska Investment Group, L.P., Vanguard Group Inc, CI Private Wealth, LLC, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Geode Capital Management, Llc, BlackRock, Inc., VEXMX - Vanguard Extended Market Index Fund Investor Shares, Blair William & Co/il, IWC - iShares Micro-Cap ETF, and Pnc Financial Services Group, Inc. Institutions hold 7.75% of the company's stock, while insiders hold 17.79%. The company was co-founded by Sherif Abdou, M.D., and Amir Bacchus, M.D.